Today: 7 February 2026
Subscribe
Browse Category

ASX:CSL News 12 December 2025 - 14 January 2026

CSL share price slips after ASX close: what investors watch next for ASX:CSL ahead of February results

CSL share price slips after ASX close: what investors watch next for ASX:CSL ahead of February results

CSL Ltd shares fell 1.0% to A$173.32 Tuesday, underperforming the S&P/ASX 200, which rose 0.56%. The drop follows last year’s cut to CSL’s FY26 forecasts and a delay to the Seqirus spin-off after a sharp decline in U.S. flu vaccinations. No new company updates were released Tuesday. CSL’s next scheduled disclosure is its half-year results on Feb. 11.
13 January 2026
···
CSL Limited Stock (ASX: CSL) on 26 December 2025: Buyback Updates, Seqirus Uncertainty, and What Analysts Forecast for 2026

CSL Limited Stock (ASX: CSL) on 26 December 2025: Buyback Updates, Seqirus Uncertainty, and What Analysts Forecast for 2026

Date: 26 December 2025 (Boxing Day) CSL Limited is ending 2025 in a very un-CSL-like place: a global healthcare heavyweight with a bruised share price, a high-profile strategic rethink around its vaccines arm, and investors trying to decide whether the company’s “reset” is the bottom—or just the middle of the story. Today, there’s an important wrinkle: the ASX is closed on Boxing Day (Friday, 26 December 2025), so market moves are paused while the narrative isn’t. Australian Securities Exchange Below is what’s actually driving CSL stock right now, the latest company and sector headlines shaping sentiment, and where the main
26 December 2025
CSL Limited Stock (ASX: CSL) on 25 December 2025: Share Price, Buyback Momentum, Seqirus Uncertainty, and the 2026 Outlook

CSL Limited Stock (ASX: CSL) on 25 December 2025: Share Price, Buyback Momentum, Seqirus Uncertainty, and the 2026 Outlook

CSL Limited has spent 2025 doing something investors rarely enjoy watching in real time: a full-scale strategic reset—complete with restructuring, a wavering plan to separate its vaccines business, and a market that has been ruthlessly impatient. As of 25 December 2025 (Christmas Day), Australian markets are closed, so the best “today” snapshot for CSL Limited stock is the last ASX trading session (24 December 2025). CSL ended that session at A$171.48, down 2.38% on the day, after trading between A$171.48 and A$175.82. Investing That price level matters because it captures the whole mood: CSL is still widely viewed as a
25 December 2025
CSL Limited (ASX:CSL) Stock Update on 24 December 2025: Share Price Drops, Buyback Progress, Seqirus Uncertainty, and 2026 Analyst Forecasts

CSL Limited (ASX:CSL) Stock Update on 24 December 2025: Share Price Drops, Buyback Progress, Seqirus Uncertainty, and 2026 Analyst Forecasts

CSL Limited shares ended 24 December 2025 on a sour note, closing at A$171.48 after sliding 2.38% on the session (open A$175.60, high A$175.76, low A$171.48). Investing.com That finish matters for two reasons. First, it keeps CSL hovering close to its 52‑week low (A$168.00) after a bruising year for one of Australia’s most widely held “quality compounder” names. Investing.com Second, it lands amid a wider re‑rating story investors have been living through since August: CSL is no longer being priced like a smooth, predictable growth machine—markets are treating it like a business in the middle of a complicated reset. Below
24 December 2025
·
CSL Limited (ASX:CSL) Stock Update: Share Price, Buyback Progress, Analyst Forecasts and Key Catalysts as of 22 December 2025

CSL Limited (ASX:CSL) Stock Update: Share Price, Buyback Progress, Analyst Forecasts and Key Catalysts as of 22 December 2025

CSL Limited shares were trading around A$176 on 22 December 2025, modestly higher on the session but still nursing a steep 2025 decline that has kept the biotech heavyweight under intense investor scrutiny heading into 2026. Investing.com+2MarketWatch+2 The story around CSL stock (ASX:CSL) right now is a tug-of-war: ongoing confidence in the company’s global plasma and specialty therapies franchise versus uncertainty around its vaccine unit Seqirus, shifting guidance, and the execution risk of a major strategic reset. At the same time, CSL’s on‑market buyback has been a steady presence in daily announcements, offering a tangible signal of capital management even
22 December 2025
·
Australia Stock Market Today: ASX 200 Rises as Miners, Energy and Record Gold Lift Shares (22 December 2025)

Australia Stock Market Today: ASX 200 Rises as Miners, Energy and Record Gold Lift Shares (22 December 2025)

Australia’s sharemarket kicked off the pre-Christmas week in upbeat fashion on Monday, with the S&P/ASX 200 trading higher into the afternoon as miners and energy stocks led broad-based gains. By early afternoon in Sydney, the benchmark was up about 0.9% around 8,701 points, with most sectors in the green and risk appetite supported by stronger global leads and a fresh surge in commodities. ABC+1 But beneath the headline rise, today’s Australia stock market story is really about three forces colliding at once: Here’s what’s moving Australian stocks today, what analysts are watching next, and what the near-term forecasts are pointing
22 December 2025
········
CSL Limited Stock (ASX: CSL) Outlook on 21 December 2025: Seqirus Spin-Off Delay, Buyback Momentum, and Analyst Price Targets

CSL Limited Stock (ASX: CSL) Outlook on 21 December 2025: Seqirus Spin-Off Delay, Buyback Momentum, and Analyst Price Targets

CSL Limited (ASX: CSL) heads into the final stretch of 2025 with its share price still under pressure—but with a growing stack of “things that matter” piling up beneath the surface: a sizeable on‑market buyback steadily absorbing stock, a major US manufacturing investment designed to reinforce its plasma-therapy moat, and a high-profile strategic reset that’s trying to simplify a complex, three‑engine biotech into something the market can price with less guesswork. As of the most recent trading day (Friday, 19 December 2025), CSL shares closed at A$175.08, after a volatile month that saw the stock slide from the mid‑A$180s toward
21 December 2025
·
CSL Limited Stock (ASX:CSL): Latest News, Buyback Update, Analyst Price Targets and 2026 Outlook (20 Dec 2025)

CSL Limited Stock (ASX:CSL): Latest News, Buyback Update, Analyst Price Targets and 2026 Outlook (20 Dec 2025)

CSL Limited (ASX:CSL; USOTC:CSLLY) has spent 2025 reminding the market of an awkward truth: even “defensive” healthcare giants can deliver very non-defensive share price swings. After a year dominated by vaccine-market volatility, a reshaped strategy for CSL Seqirus, and investor nerves around China pricing, the stock heads into late December with a familiar question hanging in the air—is CSL Limited stock a bruised blue-chip bargain, or a business still working through its hardest chapter? TradingView+1 As of the latest available pricing data around A$175 (weekend markets closed), CSL is trading much closer to its 52‑week lows than its highs (52‑week
20 December 2025
CSL Limited Stock (ASX: CSL): Buyback Update, Analyst Forecasts, and the Key Catalysts Shaping the CSL Share Price on 18 December 2025

CSL Limited Stock (ASX: CSL): Buyback Update, Analyst Forecasts, and the Key Catalysts Shaping the CSL Share Price on 18 December 2025

CSL Limited (ASX: CSL) spent much of 2025 reminding investors of a brutal truth: even world-class biopharma franchises can get whacked when costs, policy, and sentiment all lean the wrong way at the same time. On 18 December 2025, the CSL share price was A$174.57 (delayed), up 0.68% on the day after trading between A$171.64 and A$174.65. Intelligent Investor The day’s most concrete “fresh” news is a buyback update—but the real story investors are pricing is broader: the post-pandemic reset in flu vaccination demand (and politics around vaccines), margin recovery in plasma, China-linked albumin uncertainty, and whether CSL’s cost-and-capital reset
18 December 2025
·
CSL Limited Stock (ASX:CSL) Today: Buyback Update, Macquarie Downgrade, and What Analysts Forecast for 2026 (Dec 17, 2025)

CSL Limited Stock (ASX:CSL) Today: Buyback Update, Macquarie Downgrade, and What Analysts Forecast for 2026 (Dec 17, 2025)

CSL Limited shares ended Wednesday, December 17, 2025 lower as investors digested a fresh on-market buyback update and the lingering impact of broker downgrades that have reshaped sentiment around one of Australia’s most widely held healthcare names. CSL (ASX: CSL; USOTC: CSLLY) closed at A$172.77, down 2.47% on the day, after trading between A$172.75 and A$176.83 with roughly 800,720 shares changing hands. Investing.com The move keeps CSL near the bottom end of its recent range. Investing.com’s data shows a 52‑week span of A$168.00 to A$290.32, and a -38.60% change over the past year, illustrating just how sharply the market has
17 December 2025
CSL Limited Stock (ASX:CSL): Buyback Update, Analyst Price Targets and the 2026 Outlook (16 Dec 2025)

CSL Limited Stock (ASX:CSL): Buyback Update, Analyst Price Targets and the 2026 Outlook (16 Dec 2025)

CSL Limited (ASX:CSL) shares remained under pressure on Tuesday as investors weighed a fresh buyback update against a still-choppy outlook for earnings growth. The stock traded around A$177–178 in afternoon trade, extending a volatile stretch that has left the biotech giant materially lower in 2025. Intelligent Investor+1 While CSL remains one of the ASX’s most globally significant healthcare businesses, the market narrative has shifted sharply in recent months: near-term uncertainty at CSL Seqirus (vaccines), scrutiny over growth assumptions, and debate over how quickly CSL Behring’s plasma therapies can rebuild margins have all become central to the investment case. Below is
16 December 2025
··
CSL Limited Stock (ASX: CSL) Sinks on Macquarie Downgrade: Today’s News, Analyst Forecasts, and the 2026 Catalysts Investors Are Watching

CSL Limited Stock (ASX: CSL) Sinks on Macquarie Downgrade: Today’s News, Analyst Forecasts, and the 2026 Catalysts Investors Are Watching

CSL Limited (ASX: CSL) is back in the spotlight on Monday, 15 December 2025 — and not for the reasons long-term holders are used to. After years of being treated as the ASX’s “defensive growth” heavyweight, CSL stock is now trading around the A$180 level, with investors weighing fresh broker caution against a still-solid consensus view that the shares are undervalued. Investing.com+1 The day’s CSL share price action is being framed by two big developments: a reported Macquarie downgrade that slashed its target price, and CSL’s own on-market buy-back update lodged with the ASX. Add in a bruising 2025 performance
15 December 2025
·
CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited shares closed Friday at A$183.93, ending a volatile week only slightly lower overall after a sharp rebound into the weekend. Investors are weighing two very different storylines at once: encouraging long-term clinical data for CSL’s hemophilia B gene therapy HEMGENIX, and fresh scrutiny on Australia’s onshore vaccine manufacturing deals tied to CSL Seqirus — all while CSL continues to steadily mop up stock through its A$750 million on-market buyback. Global Newsroom | CSL+4Yahoo Finance+4Intelligent Investor+4 Below is what moved CSL this week, the most important news in the last few days, and what to watch in the week
14 December 2025
··
CSL Limited (ASX: CSL) Stock News Today: Buyback Update, Seqirus Uncertainty, and Analyst Forecasts for 2026

CSL Limited (ASX: CSL) Stock News Today: Buyback Update, Seqirus Uncertainty, and Analyst Forecasts for 2026

Published: December 12, 2025 CSL Limited stock (ASX: CSL) is back in the spotlight on December 12, 2025, with fresh disclosure showing the company’s on-market share buyback is still running at pace—while investors continue weighing a messy mix of catalysts: vaccine-market volatility, government scrutiny of Australia’s “sovereign manufacturing” deals, and a pipeline story that just landed in The New England Journal of Medicine. As of today, Investing.com shows CSL trading around A$182.42, versus a previous close of A$178.81, with an intraday range of A$179.45–A$182.72 and a 52-week range of A$168.00–A$290.32. Investing.com Below is a detailed wrap of the most relevant
12 December 2025
·
1 2 3

Stock Market Today

HSBC share price bounces back after BoE split vote — what to watch before Feb 25 results

HSBC share price bounces back after BoE split vote — what to watch before Feb 25 results

7 February 2026
HSBC shares closed up 2.2% at £13.06 on Friday, reversing Thursday’s drop as traders weighed possible Bank of England rate cuts and awaited the bank’s annual results on Feb. 25. The FTSE 100 rose 0.6%, with major UK banks also gaining. HSBC is also preparing to cut some banker bonuses and push out underperformers amid a cost reset. Key UK, U.S., and euro zone economic data are due next week.
Agricultural Bank of China 601288 A-shares slide as tech rout bites; inflation data is the next test

Agricultural Bank of China 601288 A-shares slide as tech rout bites; inflation data is the next test

7 February 2026
Agricultural Bank of China’s A shares closed down 0.45% at 6.67 yuan in Shanghai Friday, with turnover at 2.24 billion yuan. The bank’s A-share capital remained unchanged at 319.24 billion shares as of Jan. 31. Mainland and Hong Kong stocks fell after a global tech selloff and a sharp drop in silver futures. China’s January CPI data is due Feb. 11, with trading expected to thin ahead of the Lunar New Year break.
Palantir stock price rebounds after AI shakeout — what traders watch next week

Palantir stock price rebounds after AI shakeout — what traders watch next week

7 February 2026
Palantir Technologies shares rose 4.5% to $135.90 Friday after reporting a 70% jump in Q4 revenue to $1.407 billion and forecasting 61% revenue growth in 2026. The stock rebounded from a 6.8% drop Thursday, triggered by concerns over Big Tech capital spending and AI’s impact on software demand. A new partnership with Cognizant and U.S. government policy shifts kept Palantir in focus. Director Alexander D. Moore sold 20,000 shares on Feb. 2.
Go toTop